Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Jillian Jernigan

Advanced Practice Midwife Milton, FL Nurse Practitioner

NPI 1902382468 CMS profile 10950671

5942 Berryhill Rd, Milton, FL 32570

Open in the dashboard

General payments

$6,135

348 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jillian Jernigan of Milton, FL is reported in the CMS Open Payments database as having received $6,135 across 348 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Advanced Practice Midwife profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $132 7
2023 General $2,657 128
2022 General $1,679 107
2021 General $1,667 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jillian Jernigan
  • Advanced Practice Midwife median
  • Middle half of Advanced Practice Midwife
  • National median

In program year 2025, general payments to Jillian Jernigan were reported at $0. Among 4,127 Advanced Practice Midwife profiles paid that year, the median was $71 and the middle half received between $28 and $161.

Show as a table
Year Jillian Jernigan Advanced Practice Midwife median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,667 $57 $22–$142 $132
2022 $1,679 $61 $23–$157 $149
2023 $2,657 $68 $26–$167 $160
2024 $132 $63 $25–$142 $164
2025 $0 $71 $28–$161 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $745 63 payments
  2. Almatica Pharma LLC $457 22 payments
  3. Astellas Pharma US Inc $443 9 payments
  4. Novo Nordisk Inc $375 21 payments
  5. Axsome Therapeutics, Inc. $372 14 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $265 22 payments
  7. Lilly USA, LLC $263 17 payments
  8. Kowa Pharmaceuticals America, Inc. $260 19 payments
  9. AstraZeneca Pharmaceuticals LP $220 11 payments
  10. GlaxoSmithKline, LLC. $219 14 payments
  11. Other $2,515 136 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $5,777 343 payments
  2. Education $358 5 payments
Products named General payments · program years 2021–2024
  1. LOREEV XR $457 22 payments
  2. RYBELSUS $285 15 payments
  3. Sunosi $266 10 payments
  4. Ozempic $265 14 payments
  5. Kerendia $265 22 payments
  6. Livalo $260 19 payments
  7. VRAYLAR $237 18 payments
  8. TRELEGY ELLIPTA $219 14 payments
  9. SYNTHROID $217 11 payments
  10. NURTEC ODT $204 12 payments
  11. Other $5,092 301 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

402

Median for Certified Nurse Midwife: 28

Drug cost

$46,102

Median for Certified Nurse Midwife: $1,314

Branded share of claims

21.4%

Median for Certified Nurse Midwife: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 19 $20,362
Ozempic Semaglutide Brand 21 $20,229
Estradiol Generic 14 $915
Diclofenac Sodium Generic 17 $472
Rosuvastatin Calcium Generic 29 $427
Omeprazole Generic 24 $409
Ondansetron Odt Ondansetron Brand 12 $346
Tizanidine Hcl Generic 16 $338
Duloxetine Hcl Generic 17 $328
Gabapentin Generic 18 $276

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,212 Part D prescribers listed as Certified Nurse Midwife; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOREEV XR
  • Almatica Pharma LLC $30
$30 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $19
$19 — —
XYOSTED
  • Antares Pharma, Inc. $18
$18 — —
Azstarys
  • Corium, Inc. $16
$16 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record